The role of angiotensin II receptor blockers in the treatment of heart failure patients

Congestive Heart Failure

Volumn 9, Issue 1, 2003, Pages 29-34

  Theal, Michael ^a   Demers, Catherine ^a   McKelvie, Robert S ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; PLACEBO; SPIRONOLACTONE; VALSARTAN;

COUGHING; HEART FAILURE; HEART FUNCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MORBIDITY; MORTALITY; QUALITY OF LIFE; REVIEW;

EID: 0037231259     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2003.tb00019.x     Document Type: Review

References (37)

1. Flather M, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE Inhibitor Myocardial Collaborative Group. Lancet. 2000;355:1575-1581.
2. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet. 1999;353:2001-2007.
3. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II: a randomised trial. Lancet. 1999;353:9-13.
4. Pitt B, Zannad F, Remme WJ, et al., for the Randomized Aldactone Evaluation Study Investigators. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
5. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533.
6. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208-225.
7. Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Cardiol. 1992;20:301-306.
8. Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and renin-angiotensin system and their relationship to hemodynamic abnormalities in congestive heart failure. Am J 1982;49:1659-1666.
9. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeKT II. Circulation. 1993;87(suppl VI):40-48.
10. Weber KT, Sun Y, Katawa LC. Wound healing following myocardial infarction. Clin Cardiol. 1996;19(6):447-455.
11. Carson PE. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J. 2000;140:361-366.
12. Benedict CR, Francis GS, Johnstone DE, et al., for the SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol. 1995;75:1151-1157.
13. Brunner-La Rocca HP, Vaddadi G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol. 1999;33(5):1163-1173.
14. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21:53-57.
15. Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-149.
16. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257-267.
17. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995;(suppl N):103-106.
18. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J Biol Chem. 1990;265(36):22348-22357.
19. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type II receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type II receptors. J Clin Invest. 1997;90(4):1926-1935.
20. Riegger GA, Bouzo H, Petr P, et al., for the STRETCH investigators. Improvement of exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation. 1999;100:2224-2230.
21. Granger CB, Ertl G, Kuch J, et al., for the Stud), of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Investigators. Randomized trial of candesartan cilexetil in the treatment of congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609-617.
22. Crozier I, Ikram H, Arvan N, et al., for the Losartan Hemodynamic Study Group. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 1995;91:691-697.
23. Havranek EP, Thomas I, Smith WB, et al., for the Irbesartan Heart Failure Group. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 1999;33:1174-1181.
24. Mazayev VP, Fomina IG, Kazakov EN, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol. 1998;65:239-246.
25. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 1997;30: 983-1017.
26. Dickstein K, Chang P, WillenHeimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26:438-445.
27. Pitt B, Segal R, Martinez FA, et al., on behalf of the ELITE study investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
28. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the anti-growth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91:2043-2048.
29. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: the RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056-1064.
30. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe heart failure. Circulation. 1999;99:990-992.
31. Tonkon M, Awan N, Niazi I, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Int J Clin Pract. 2000;54:11-18.
32. Murdoch DR, McDonagh TA, Farmer R, et al. ADEPT: addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001;141:800-807.
33. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study (ELITE II). Lancet. 2000;355:1582-1587.
34. Cohn JN, Tognami G, Glazen R, et al. A rationale and design of the valsartan heart failure trial: a large multinational trial to assess the effects of valsartan, an ARB, on morbidity and mortality in chronic heart failure. J Card Fail. 1999;5:155-160. Results presented at the American Heart Association Scientific Sessions. New Orleans, LA; November, 2000.
35. Jong P, Demers C, McKelvie RS, et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39(3):460-470.
36. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in Heart failure - Assessment of Reduction in Mortality and Morbidity(CHARM): rationale and design. J Card Fail. 1999;5(3):276-282.
37. Unger T. Significance of angiotensin type I receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol. 1999;84:9S-15S.